Intermittent Preventive Treatment in Infant in Mali
Information source: University of Bamako
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Malaria
Intervention: Sulfadoxine pyrimethamine (Drug)
Phase: N/A
Status: Completed
Sponsored by: University of Bamako Official(s) and/or principal investigator(s): Alassane Dicko, MD, Principal Investigator, Affiliation: Faculty of Medicine, Pharmacy and Dentistry; University of Bamako Ogobara K Doumbo, MD, Study Director, Affiliation: Faculty of Medicine, Pharmacy and Dentistry; University of Bamako
Summary
Studies have shown that Intermittent preventive treatment in infants (IPTi) with
Sulfadoxine-pyrimethamine (SP)reduced the incidence of clinical malaria and anemia without
modifying infants' serological response to EPI vaccines. Thus IPTi was seen as a potential
public health tool of great benefit to the children of Africa and a logical addition to the
Immunization Plus package. The objectives of this operational researcher were
- to develop an implementation model for IPTi in the health care system in Mali
- to assess its impact on the EPI vaccines and other health interventions coverage
- and on molecular makers of resistance to SP
Clinical Details
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Primary outcome: EPI vaccines and other health interventions coverageMolecular makers of resistance of P. falciparum to Sulfaxodine- pyrimethamine
Detailed description:
The study was implemented in districts of the region of Koulikoro; the district of Koulikoro
and the district of Kolokani. The whole district of Koulikoro was covered by the
intervention while in Kolokani, the 22 health areas (sub districts) were randomized in 1: 1
ratio with the intervention in 11 health areas and the other 11 serving as control for the
assessment of the impact of IPTi implementation on EPI vaccines and other health
interventions coverage as well as its impact on the resistance to SP. The implementation
consisted of administration of ½ tablet of Sulfadoxine - Pyrimethamine with EPI vaccines
(DTP2, DTP3 and Measles vaccine) from December 2006 to December 2007.
Eligibility
Minimum age: N/A.
Maximum age: 23 Months.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Resident of Kolokani, Mali
- Age less than 24 months
Exclusion Criteria:
- Not Resident of Kolokani
- Age of 24 months or above
Locations and Contacts
Malaria Research & Training Center; Faculty of Medicine, Pharmacy and Dentistry, University of Bamako, Bamako 0000, Mali
Additional Information
Starting date: October 2006
Last updated: October 3, 2008
|